Inactive Instrument

Arena Pharmaceuticals

Equities

ARNA

US0400476075

Arena Pharmaceuticals, Inc. Appoints Doug Manion, M.D., F.R.C.P. , as Executive Vice President of Research Development

July 20, 2021 at 07:28 am EDT

Arena Pharmaceuticals, Inc. announced the appointment of Douglas J. Manion, M.D., F.R.C.P. as Executive Vice President of Research Development, reporting to Amit D. Munshi, President and CEO of Arena. Dr. Manion brings more than 20 years of pharmaceutical industry experience spanning three large companies, including work in all of Arena's therapeutic areas. Dr. Manion joins Arena after serving as CEO of Kleo Phamaceuticals, a private biotechnology company focused on innovative small molecule immunotherapeutics, from 2017 until its acquisition by Biohaven Holdings in January 2021.

Latest news about Arena Pharmaceuticals

Longboard Pharmaceuticals, Inc. and Arena Pharmaceuticals, Inc. Executes into Second Amendment to That Certain License Agreement	22-09-19	CI
Arena Pharmaceuticals, Inc.(NasdaqGS:ARNA) dropped from S&P Biotechnology Select Industry Index	22-03-15	CI
Arena Pharmaceuticals, Inc.(NasdaqGS:ARNA) dropped from S&P TMI Index	22-03-15	CI
Arena Pharmaceuticals, Inc.(NasdaqGS:ARNA) dropped from S&P Global BMI Index	22-03-15	CI
Pfizer Completes $6.7 Billion Acquisition of Arena Pharmaceuticals	22-03-11	MT
Arena Pharmaceuticals, Inc. Announces Board Changes	22-03-11	CI
Arena Pharmaceuticals, Inc.(NasdaqGS:ARNA) dropped from NASDAQ Biotechnology Index	22-03-11	CI
Arena Pharmaceuticals, Inc.(NasdaqGS:ARNA) dropped from NASDAQ Composite Index	22-03-11	CI
Pfizer Inc. completed the acquisition of Arena Pharmaceuticals, Inc..	22-03-10	CI
Arena Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-02-23	CI
Arena Pharmaceuticals Extends Q4 Loss, Reports Higher Revenue	22-02-23	MT
Earnings Flash (ARNA) ARENA PHARMACEUTICALS Reports Q4 Revenue $54,000, vs. Street Est of $0.732M	22-02-23	MT
Earnings Flash (ARNA) ARENA PHARMACEUTICALS Reports Q4 Loss $-2.54, vs. Street Est of $-2.23	22-02-23	MT
Arena Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2021	22-02-23	CI
Avalo Therapeutics Promotes Neil to Chief Executive, Sullivan to Finance Chief	22-02-17	MT
North American Morning Briefing : Stock Futures -3-	22-02-11	DJ
North American Morning Briefing : Bonds Yields -3-	22-02-10	DJ
HC Wainwright Downgrades Arena Pharmaceuticals to Neutral From Buy; Price Target is $100	22-02-09	MT
Transcript : Arena Pharmaceuticals, Inc. - Shareholder/Analyst Call	22-02-02
North American Morning Briefing : Dow Futures Dip -2-	21-12-22	DJ
Cantor Fitzgerald Downgrades Arena Pharmaceuticals to Neutral From Overweight, Adjusts Price Target to $100 From $93	21-12-21	MT
PUMP / DUMP #15 : The week's gainers and losers	21-12-17
North American Morning Briefing :Stocks Seen on Hold as Fed Looms	21-12-15	DJ
Arena's PT Hiked to $100 by RBC in Line With Pfizer's Proposed Bid; Downgraded to Sector Perform as no Deal Hurdles Seen	21-12-14	MT
Citigroup Downgrades Arena Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $100 From $101	21-12-14	MT

Chart Arena Pharmaceuticals

Duration

Period

More charts

Company Profile

Arena Pharmaceuticals, Inc. is a biopharmaceutical company focused on delivering transformational medicines with optimized pharmacology and pharmacokinetics to patients globally. The Company's clinical programs include Etrasimod, which is an oral, selective sphingosine 1-phosphate (S1P), receptor modulator, designed to provide systemic and local cell modulation by targeting S1P receptor subtypes one, four and five. Olorinab, an orally available, potent, peripherally acting, selective, full agonist of the CB2 receptor, is an internally discovered investigational drug candidate. APD418 is an adrenergic receptor (AdrR) antagonist and cardiac myotrope designed to regulate myofilament calcium sensitivity in order to improve contractility without inducing the adverse events associated with available inotropes. Temanogrel is a peripherally acting and selective 5HT2a inverse agonist designed to inhibit serotonin (5-HT) mediated amplification of platelet aggregation and vasoconstriction.

Sector

More about the company